TL;DR: Hims & Hers (NYSE: HIMS) reported a net loss for Q1 2026 and issued Q2 revenue guidance below consensus, causing shares to fall 13% in after-hours trading despite the recent high-profile launch of its GLP-1 weight loss drug offering.
What happened
After the market close on May 12, 2026, Hims & Hers Health, Inc. reported a Q1 2026 net loss of $(0.05) per share, missing consensus estimates of a $(0.02) loss. The company issued second-quarter revenue guidance in the range of $295 million to $305 million. The $300 million midpoint of this guidance falls short of the pre-existing analyst consensus of $312 million, implying a significant deceleration from prior growth expectations.Why now — the mechanism
The market's negative reaction is a direct consequence of guidance failing to meet expectations built around the company's entry into the GLP-1 weight-loss market. Following its March 2026 deal with Novo Nordisk to offer Wegovy, investors had priced in a significant and immediate revenue ramp. The weak Q2 forecast signals that the associated costs—primarily marketing spend for customer acquisition and infrastructure to support the new offering—are compressing near-term profitability and cash flow more than models had anticipated. The telehealth space for weight management is intensely competitive, and this guidance suggests Hims is engaging in a costly land-grab phase where margins are sacrificed for market share, a scenario investors are now forced to discount more heavily.What this means
For analysts, forward estimates for HIMS's profitability and free cash flow must be revised downward for the next two to three quarters. The primary adjustment will be to Sales & Marketing expense as a percentage of revenue, which is now expected to remain elevated. The stock's valuation, previously supported by a pure top-line growth narrative, now faces multiple compression as the focus shifts to the unit economics of the GLP-1 segment and the timeline to achieve accretive margins. The key actionable risk is execution; failure to demonstrate a clear path to margin expansion in the GLP-1 segment by the Q2 2026 report could trigger a further de-rating of the stock. As of 2026-05-13T04:40:12Z, HIMS shares were trading at $18.50 in after-hours, down from a market close of $21.26.What to watch next
The primary data-driven catalyst will be the company's Q2 2026 earnings release, scheduled for early August 2026. This report will provide the first full quarter of financial data on the GLP-1 offering's performance, including crucial metrics on subscriber acquisition cost (SAC) and lifetime value (LTV). Any interim announcements at investor conferences regarding subscriber growth or updates to the full-year outlook will also be critical market-moving events. Cross-verified across 1 independent sources · Intel Score 1.000/1.000 — computed from signal velocity, source diversity, and event significance.This article is not financial advice.